Ace Therapeutics provides the most specialized services to clients researching autoimmune hepatitis (AIH) worldwide. Our goal is to promote research advances in all liver diseases, including AIH, based on our technology and experience, and to overcome liver disease challenges early.
AIH is an immunoinflammatory chronic liver disease with dynamic and rather heterogeneous disease manifestations. The disease is still not completely conquered and new diagnostic techniques and treatments need to be developed for it. We have extensive research experience in the field of liver disease.
What Can We Do?
Based on extensive experience in drug development and knowledge of developing new drugs based on gut microorganisms, Ace Therapeutics offers exclusive services for different directions of the development of liver disease drugs to meet the needs of different research protocols.
The overall goal of AIH therapy is to induce and maintain complete suppression of inflammatory activity and prevent disease progression to cirrhosis and liver dysfunction. Therefore, our therapy development services for AIH focus on controlling inflammation and immune aspects. We provide comprehensive services for drug development against potential targets of AIH and the development of monoclonal antibodies against immune responses.
- mTOR Inhibitor
The mammalian target of rapamycin (mTOR) is a specific intracellular protein kinase that regulates cell proliferation, motility, and survival. In contrast, mTOR inhibitors tend to have potent immunosuppressive and anti-proliferative properties.
- Calcineurin Inhibitor
Calcineurin Inhibitors can exert immunosuppressive effects by inhibiting Treg activation and IL-2 production.
- Thiopurines
Thiopurine is an immunosuppressive drug that is anti-inflammatory by inhibiting T-cell activation and proliferation.
- Monoclonal Antibody
Some monoclonal antibodies have demonstrated good therapeutic efficacy in the treatment of AIH, especially in patients with refractory or difficult-to-treat AIH, such as Rituximab (a monoclonal B cell-depleting antibody) and infliximab (a humanized chimeric monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor alpha).
- Diagnostics Development for AIH
AIH can be asymptomatic or present in various forms, ranging from subclinical disease to acute liver failure and end-stage liver disease. This poses a great challenge for the diagnosis of AIH but also highlights the importance of developing diagnostic techniques for AIH. Based on our extensive research experience in liver disease and advanced technology in the field of disease diagnosis, we are committed to providing you with the most professional and appropriate technical services to support your research project.
Currently, the diagnosis of AIH relies on indicative clinical, serological, biochemical, and histological findings. We are committed to refining our diagnostic techniques based on serological and biochemical tests to better diagnose AIH.
- Autoantibodies are the key to the effective diagnosis of AIH. We will develop a sensitive and accurate antibody test for the effective diagnosis of AIH based on the characteristics of AIH.
- Liver biopsy is an effective method for the diagnosis of liver disease. We will optimize the procedure and test index of liver biopsy to achieve a more accurate and convenient diagnosis of AIH.
Ace Therapeutics has extensive research experience in the field of liver disease. We focus on all aspects of the liver disease field, and with our experience and technology, we are committed to advancing research in AIH. If you would like to learn more about our services, please feel free to contact us.
Reference
- Komori, A. Recent updates on the management of autoimmune hepatitis. Clin Mol Hepatol, 2021. 27(1): p. 58-69.
Related Services
Our products and services are for research use only and can not be used for diagnostic or other purposes.
